Posted by Michael Wonder on 15 Nov 2022
Imfinzi plus chemotherapy recommended for approval in the EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer
14 November 2022 - Positive opinion based on TOPAZ-1 Phase 3 trial updated survival results showing Imfinzi combination reduced risk of death by 24% versus chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union for the first-line treatment of adult patients with unresectable or metastatic biliary tract cancer in combination with chemotherapy (gemcitabine plus cisplatin).
